199 related articles for article (PubMed ID: 22308267)
1. "Picolog," a synthetically-available bryostatin analog, inhibits growth of MYC-induced lymphoma in vivo.
DeChristopher BA; Fan AC; Felsher DW; Wender PA
Oncotarget; 2012 Jan; 3(1):58-66. PubMed ID: 22308267
[TBL] [Abstract][Full Text] [Related]
2. Bryostatin analog: improving on Nature's design.
Boger D
Oncotarget; 2012 Feb; 3(2):116-7. PubMed ID: 22416072
[No Abstract] [Full Text] [Related]
3. Preclinical and Clinical Studies on Bryostatins, A Class of Marine-Derived Protein Kinase C Modulators: A Mini-Review.
Raghuvanshi R; Bharate SB
Curr Top Med Chem; 2020; 20(12):1124-1135. PubMed ID: 32209043
[TBL] [Abstract][Full Text] [Related]
4. A cellular model of Alzheimer's disease therapeutic efficacy: PKC activation reverses Abeta-induced biomarker abnormality on cultured fibroblasts.
Khan TK; Nelson TJ; Verma VA; Wender PA; Alkon DL
Neurobiol Dis; 2009 May; 34(2):332-9. PubMed ID: 19233276
[TBL] [Abstract][Full Text] [Related]
5. Bryostatin and its synthetic analog, picolog rescue dermal fibroblasts from prolonged stress and contribute to survival and rejuvenation of human skin equivalents.
Khan TK; Wender PA; Alkon DL
J Cell Physiol; 2018 Feb; 233(2):1523-1534. PubMed ID: 28590053
[TBL] [Abstract][Full Text] [Related]
6. The design, synthesis, and evaluation of C7 diversified bryostatin analogs reveals a hot spot for PKC affinity.
Wender PA; Verma VA
Org Lett; 2008 Aug; 10(15):3331-4. PubMed ID: 18588309
[TBL] [Abstract][Full Text] [Related]
7. Marine natural products: bryostatins in preclinical and clinical studies.
Kollár P; Rajchard J; Balounová Z; Pazourek J
Pharm Biol; 2014 Feb; 52(2):237-42. PubMed ID: 24033119
[TBL] [Abstract][Full Text] [Related]
8. The design, computer modeling, solution structure, and biological evaluation of synthetic analogs of bryostatin 1.
Wender PA; DeBrabander J; Harran PG; Jimenez JM; Koehler MF; Lippa B; Park CM; Siedenbiedel C; Pettit GR
Proc Natl Acad Sci U S A; 1998 Jun; 95(12):6624-9. PubMed ID: 9618462
[TBL] [Abstract][Full Text] [Related]
9. A simple analogue of tumor-promoting aplysiatoxin is an antineoplastic agent rather than a tumor promoter: development of a synthetically accessible protein kinase C activator with bryostatin-like activity.
Nakagawa Y; Yanagita RC; Hamada N; Murakami A; Takahashi H; Saito N; Nagai H; Irie K
J Am Chem Soc; 2009 Jun; 131(22):7573-9. PubMed ID: 19449873
[TBL] [Abstract][Full Text] [Related]
10. Biological profile of the less lipophilic and synthetically more accessible bryostatin 7 closely resembles that of bryostatin 1.
Kedei N; Lewin NE; Géczy T; Selezneva J; Braun DC; Chen J; Herrmann MA; Heldman MR; Lim L; Mannan P; Garfield SH; Poudel YB; Cummins TJ; Rudra A; Blumberg PM; Keck GE
ACS Chem Biol; 2013 Apr; 8(4):767-77. PubMed ID: 23369356
[TBL] [Abstract][Full Text] [Related]
11. Improved protein kinase C affinity through final step diversification of a simplified salicylate-derived bryostatin analog scaffold.
Wender PA; Staveness D
Org Lett; 2014 Oct; 16(19):5140-3. PubMed ID: 25238640
[TBL] [Abstract][Full Text] [Related]
12. The bryostatins inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase C-independent mechanism: dissociation of activities using 26-epi-bryostatin 1.
Szallasi Z; Du L; Levine R; Lewin NE; Nguyen PN; Williams MD; Pettit GR; Blumberg PM
Cancer Res; 1996 May; 56(9):2105-11. PubMed ID: 8616857
[TBL] [Abstract][Full Text] [Related]
13. Substitution on the A-ring confers to bryopyran analogues the unique biological activity characteristic of bryostatins and distinct from that of the phorbol esters.
Keck GE; Poudel YB; Welch DS; Kraft MB; Truong AP; Stephens JC; Kedei N; Lewin NE; Blumberg PM
Org Lett; 2009 Feb; 11(3):593-6. PubMed ID: 19113896
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and evaluation of designed PKC modulators for enhanced cancer immunotherapy.
Hardman C; Ho S; Shimizu A; Luu-Nguyen Q; Sloane JL; Soliman MSA; Marsden MD; Zack JA; Wender PA
Nat Commun; 2020 Apr; 11(1):1879. PubMed ID: 32312992
[TBL] [Abstract][Full Text] [Related]
15. Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro.
DeChristopher BA; Loy BA; Marsden MD; Schrier AJ; Zack JA; Wender PA
Nat Chem; 2012 Sep; 4(9):705-10. PubMed ID: 22914190
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and evaluation of potent bryostatin analogs that modulate PKC translocation selectivity.
Wender PA; Baryza JL; Brenner SE; DeChristopher BA; Loy BA; Schrier AJ; Verma VA
Proc Natl Acad Sci U S A; 2011 Apr; 108(17):6721-6. PubMed ID: 21415363
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of a des-B-ring bryostatin analogue leads to an unexpected ring expansion of the bryolactone core.
Kraft MB; Poudel YB; Kedei N; Lewin NE; Peach ML; Blumberg PM; Keck GE
J Am Chem Soc; 2014 Sep; 136(38):13202-8. PubMed ID: 25207434
[TBL] [Abstract][Full Text] [Related]
18. The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-βII depletion.
Biberacher V; Decker T; Oelsner M; Wagner M; Bogner C; Schmidt B; Kreitman RJ; Peschel C; Pastan I; Meyer Zum Büschenfelde C; Ringshausen I
Haematologica; 2012 May; 97(5):771-9. PubMed ID: 22180432
[TBL] [Abstract][Full Text] [Related]
19. Total synthesis of bryostatin 16 using a Pd-catalyzed diyne coupling as macrocyclization method and synthesis of C20-epi-bryostatin 7 as a potent anticancer agent.
Trost BM; Dong G
J Am Chem Soc; 2010 Nov; 132(46):16403-16. PubMed ID: 21043491
[TBL] [Abstract][Full Text] [Related]
20. Bryostatin 1 protects protein kinase C-delta from down-regulation in mouse keratinocytes in parallel with its inhibition of phorbol ester-induced differentiation.
Szallasi Z; Denning MF; Smith CB; Dlugosz AA; Yuspa SH; Pettit GR; Blumberg PM
Mol Pharmacol; 1994 Nov; 46(5):840-50. PubMed ID: 7969070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]